The pharmaceutical company expects a 10-12% hike in sales revenues this year and a 20-25% increase in pre-tax profit.
Sopharma posted net profit in the amount of 30.63 million leva (15.66 million euros) last year, which is 39% up from 2006 (22.034 million leva,).
42% of sales revenues last year came from sales on the domestic market. Exports accounted for 64.828 million leva, which is 41% up from 2006. The relative share of sales abroad stood at 52%, compared with 52% in 2006.
89% of exports are to Russia, Ukraine, Poland, Kazakhstan and Belarus.
This year Sopharma Jsc received a First Class Investment Certificate for its 37.65 million euro project for the construction of a medical plant.
Main shareholders are Donev investments and Telso Jsc which control 25.64% and 23.77% respectively. Telecomplect and Greamery Emerging Market Fund have 20.42% and 17.08%.